Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide for DCIS Chemoprevention
NCT01372618Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jun 2011
- Primary completion
- Oct 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in ductal carcinoma in situ (DCIS), sponsored by NYU Langone Health. Started Jun 2011; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT01372618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01372618.